MX2012015112A - Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. - Google Patents

Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.

Info

Publication number
MX2012015112A
MX2012015112A MX2012015112A MX2012015112A MX2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A
Authority
MX
Mexico
Prior art keywords
pulmonary hypertension
receptor antagonists
adenosine receptor
treating pulmonary
treating
Prior art date
Application number
MX2012015112A
Other languages
English (en)
Spanish (es)
Inventor
Luiz Belardinelli
Dewan Zeng
Hongyan Zhong
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2012015112A publication Critical patent/MX2012015112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012015112A 2010-06-30 2011-06-29 Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. MX2012015112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36028910P 2010-06-30 2010-06-30
PCT/US2011/042379 WO2012003220A1 (en) 2010-06-30 2011-06-29 Use of a2b adenosine receptor antagonists for treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
MX2012015112A true MX2012015112A (es) 2013-05-28

Family

ID=44343985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015112A MX2012015112A (es) 2010-06-30 2011-06-29 Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.

Country Status (11)

Country Link
US (1) US20120003329A1 (cg-RX-API-DMAC7.html)
EP (1) EP2595630A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013533882A (cg-RX-API-DMAC7.html)
KR (1) KR20130088834A (cg-RX-API-DMAC7.html)
CN (1) CN103237548A (cg-RX-API-DMAC7.html)
AU (1) AU2011271510A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012032766A2 (cg-RX-API-DMAC7.html)
CA (1) CA2802891A1 (cg-RX-API-DMAC7.html)
EA (1) EA201291274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012015112A (cg-RX-API-DMAC7.html)
WO (1) WO2012003220A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP2017048116A (ja) * 2014-01-10 2017-03-09 国立研究開発法人国立国際医療研究センター 肺高血圧症治療薬
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
CN117597139A (zh) * 2021-03-05 2024-02-23 托斯克公司 预防或治疗药物诱导的肺功能障碍的尿苷磷酸化酶抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE307132T1 (de) 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
DE10303639B4 (de) 2003-01-30 2016-05-25 Zf Friedrichshafen Ag Vorrichtung zur Steuerung einer hydraulisch betätigbaren Kupplung eines Automatgetriebes
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
EP2311462A1 (en) * 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物

Also Published As

Publication number Publication date
EA201291274A1 (ru) 2013-12-30
EP2595630A1 (en) 2013-05-29
CN103237548A (zh) 2013-08-07
CA2802891A1 (en) 2012-01-05
JP2013533882A (ja) 2013-08-29
WO2012003220A1 (en) 2012-01-05
AU2011271510A1 (en) 2013-01-10
KR20130088834A (ko) 2013-08-08
US20120003329A1 (en) 2012-01-05
BR112012032766A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12012502512A1 (en) 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors
PH12014500355A1 (en) Lysophosphatidic acid receptor antagonists
WO2013160317A3 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
IN2012DN02735A (cg-RX-API-DMAC7.html)
IN2012DN02730A (cg-RX-API-DMAC7.html)
IN2012DN00754A (cg-RX-API-DMAC7.html)
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX2014001946A (es) Inhibidores del canal de potasio medularmente externo renal.
CY1116892T1 (el) Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MY173521A (en) Trpv4 antagonists
NZ608813A (en) Treatment of myocardial infarction using tgf - beta antagonists
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
IN2014DN06964A (cg-RX-API-DMAC7.html)
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
EA201291274A1 (ru) Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2013011465A (es) Uso de antagonista del receptor de adenosina a2b para tratar insuficiencia cardiaca y arritmia en pacientes post-infarto al miocardio.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal